Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: Leman who wrote (1060)	5/20/1998 2:00:00 PM
From: Manx	Read Replies (1) \| Respond to of 2135

From The Washington Post (Tuesday, May 19, 1998, Business section: page C12): Healthy News for Stocks and Cancer Research The Washington Post in an article about Breast Cancer Research Lifting Stocks, via Genentech's positive results in advanced human tests of a new breast cancer treatment, i.e., Herceptin.... It goes to say... If Herceptin does eventually win FDA approval, that could be good news for a financially troubled Gaithersburg company called Oncor Inc. It was the first company to win FDA approval for a genetic test that may help determine whether breast cancer patients could benefit from Herceptin. Demand for such testing is likely to soar once Herceptin is on the market ... ... ... Any comment? ps. I have a small position in ONC.